Subject Index

Acute phase response, cytokine cascade 1, 2
Allergic colitis, inflammatory bowel disease risk 119
5-Aminosalicylic acid, inflammatory bowel disease treatment 101, 147, 208, 237
Anemia, management with inflammatory bowel disease
cobalamin deficiency 164, 165
erythropoietin therapy 169
iron deficiency 162–164, 167–169
Anticipation, Crohn’s disease 24
Antioxidant defenses
glutamine supplementation effects 221–223
inflammation 66, 67, 217, 218
nutrition effects
 glutathione 68–70
 lipid intake 72–74, 78–81
 metallic micronutrients 67, 68, 77, 78
 miscellaneous antioxidants 67, 68
 protein and amino acid intake 68–71
 sites of activity 75, 76
 vitamin A 72
 vitamin C 71
 vitamin E 71, 78
Apoptosis
 inhibition by glutamine during parenteral nutrition administration 219, 220
 regulation in intestinal epithelial cell
 51, 53, 54, 59, 60
 ASCA test, distinguishing Crohn’s disease from ulcerative colitis 89, 117, 118, 120
 Azathioprine, inflammatory bowel disease treatment 139, 152, 237
 Bcl-2, apoptosis regulation in intestinal epithelial cells 54
 Biopsy, inflammatory lesions in gastrointestinal tract 95
 Bowel rest, see Total parenteral nutrition
 Budesonide, inflammatory bowel disease treatment 139, 152
 Butyrate
 effects on intestinal gene expression 135–137
 inflammation control 145
 Candidate gene approach
 association studies 26, 27
 founder effect 28, 29
 genes in inflammatory bowel disease 29, 30, 39
 transmission disequilibrium test 27, 28
 CD44 variant 6, expression in inflammatory bowel disease(s) 98
 CDP571, inflammatory bowel disease treatment
 anti-antibody response 247
 cost 252
CDP571, inflammatory bowel disease treatment (continued)
Crohn's disease treatment 243
features 241
multiple infusions 244
nutrition response 254, 255
precautions
  cancer 249, 255
  children 249, 253, 254
  dosing 250
  drug absorption 249, 254
  extraintestinal manifestations 249
  immunosuppression 248
  infection 248
  infusion reactions 248
  long-acting effects 248, 249
  pregnancy 247, 248
  regulatory approval 253
  safety 246
  therapeutic subgroup identification 244, 245, 250
  ulcerative colitis treatment 245
Chemokines
  inflammatory bowel disease roles 48, 49
  lumen signaling to mucosal immune system 128, 129
Chromosome 12, susceptibility locus in inflammatory bowel disease 33, 34, 37, 38
Chromosome 16, susceptibility locus in inflammatory bowel disease 32, 34, 37, 38
Cobalamin deficiency, management with inflammatory bowel disease 164, 165
Colon cancer
  endoscopic surveillance 103, 115
  risk with ulcerative colitis 86, 102, 104
Colonoscopy, see Endoscopy
Corticosteroids, inflammatory bowel disease treatment 139, 175, 176, 178, 179, 184, 237
Crohn's disease
  activity indexes 89, 101, 103, 183
  complications and management
    anemia
      cobalamin deficiency 164, 165
      erythropoietin therapy 169
      iron deficiency 162–164, 167–169
      osteoporosis 161, 162
      overview 88, 89
  course 89
diagnosis
  children
    barium studies 109–111
    colonoscopy 108, 109
differential diagnosis 115
  difficulty of diagnosis 107
  histological diagnosis 110
  immunodeficiency and Crohn's-like conditions 113
  laboratory tests 108, 109, 112, 117, 118, 120
  overview 108
  radiological features 111
  clinical trial criteria 99
diagnosis
  infectious colitis 97
  overview 96
differentiation from ulcerative colitis 98, 99, 102, 104, 105
  inflammatory bowel disease
  therapeutic subgroup identification 244, 245, 250
treatment, see Treatment, inflammatory bowel disease
CT3211, nutritional therapy in children with Crohn's disease
  composition 188, 189, 197
  duration of treatment 192, 193
  patient selection for trial 188
  relapse rate 193, 194
  response to 8 weeks of treatment
    activity index 189
    C-reactive protein concentration 190
    endoscopy 190, 198
    histology 191, 198
    mucosal cytokines 191, 192, 194, 167–196
  symptoms 87, 88, 93, 94
discovery 7
  incidence studies, see Incidence studies, inflammatory bowel disease
  nutritional consequences 88
  pathology 87
  protein-energy malnutrition, overview 3, 4
  risk factors, see Risk factors, inflammatory bowel disease
  therapeutic subgroup identification 244, 245, 250
  treatment, see Treatment, inflammatory bowel disease
Diet
- gene expression regulation
  - breast milk and gene expression in enterocytes 125, 126
  - butyrate 135–137
  - enterocyte adaptation 123–125
- lumen signaling to mucosal immune system
  - chemokine secretion 128, 129
  - class II major histocompatibility complex and invariant chain expression 129, 130, 132
  - insulin-like growth factor binding proteins 130, 131
- overview 127, 128
- therapeutic implications 131, 132
- operons 121
  - overview 122, 123
  - polarity of nutrient-gene interactions in epithelia 123
- inflammatory bowel disease risk factors 13, 14, 18–21
- inflammatory bowel disease treatment, see CT3211, Enteral nutrition, Fish oil, Glutamine supplementation, Total parenteral nutrition

Docosahexaenoic acid, see Fish oil

Eicosapentaenoic acid, see Fish oil

Elimination diets, Crohn’s disease treatment 145, 147

Endoscopy
- colon cancer surveillance 103, 115
- inflammatory bowel disease diagnosis in children
  - Crohn’s disease 108, 109
  - ulcerative colitis 114, 115
- inflammatory lesion demonstration in gastrointestinal tract 95

Enteral nutrition, inflammatory bowel disease treatment
- adjunctive support vs primary treatment 174
- disease remission compared to drug therapy 142–144, 146, 147
- growth retardation in children
  - mechanisms 172, 173
  - prevalence in Crohn’s disease 171, 172
  - reversal 145, 150
- gut-trophic growth factors 217

intestinal atrophy reversal after total parental nutrition 157, 158
meta-analysis of studies 144, 174–177
pediatric treatment, see also CT3211
  - acceptance and compliance 180, 181, 187
corticosteroid efficacy comparison 175, 176, 178, 179, 183
cyclical nutrition 180
- drug treatment factors 149
- early recurrence of active disease 180
- elemental vs non-elemental diets 179
- formula composition and efficacy 178
- mechanism of action 177, 178, 187, 188
- meta-analysis of efficacy 174–177
- site-specific efficacy 179, 180
- supplemental nutrition 180
- preoperative therapy 150
- relapse 149

Epithelial cell, see Intestinal epithelial cell

Erythropoietin therapy, anemia 169

FAS, apoptosis regulation in intestinal epithelial cells 53, 54, 59

Fish oil
- anti-inflammatory activities 72–74, 78–81, 199, 200, 209
- fish consumption effects on inflammatory bowel disease treatment 212, 213
- supplementation in inflammatory bowel disease treatment
  - clinical studies, history 201–203
  - rationale 200
- relapse prevention 4, 43
- study of 45% EPA/20% DHA derivative
  - absorption and tolerance 204, 205
  - composition of supplement 203, 204, 211–215
  - Crohn’s disease treatment 205–208
  - duration of treatment 212
  - gut resection patient treatment 208
  - study design 204
- ulcerative colitis treatment 209
- vitamin content 212, 213
Subject Index

Fistula, management with total parenteral nutrition 159, 167
Flavor packets, diet compliance effects 153
Glutamine supplementation, inflammatory bowel disease treatment
alternative compounds for administration 224, 232
antioxidant capacity effects 221–223
cell swelling hypothesis in mechanism 231
clinical trials and beneficial effects 224–227, 230
conditional essentiality 218, 219
experimental colitis models 223
experimental short bowel syndrome and jejunal transplantation 220
gut barrier function effects 221
gut trophic growth factor coadministration 233
immune response 226, 232
small peptide transport 224, 225, 234
stability of preparations 223, 224
tolerance 225, 227
total parenteral nutrition 157, 158, 232, 233
trophic effects during parenteral nutrition administration 219, 220
Glutathione
anti-inflammatory activity 68–70
levels 219
Growth retardation in children
mechanisms 172, 173
prevalence in Crohn’s disease 171, 172
reversal by enteral nutrition 145, 150
Hereditary, inflammatory bowel disease
candidate gene approach using association studies 26–30
familial studies 23–25, 37, 42
linkage studies 30–34
susceptibility loci 32–35
HLA-B27, transgenic rats and inflammatory bowel disease development 43, 44
HLA-DRB1, linkage with inflammatory bowel disease 34
Incidence studies, inflammatory bowel disease
age-specific incidence 10, 24
cohort effects 11
ethnicity and geographical differences 9, 10, 18, 20, 21
gender differences 10, 11
historical overview 7–9, 19
Indeterminate colitis, features 90, 91
Infliximab, inflammatory bowel disease treatment
anti-antibody response 246
cost 252
Crohn’s disease treatment 241–243
features 241
multiple infusions 243, 244
nutrition response 254, 255
precautions
cancer 249, 255
children 249, 253, 254
dosing 250
drug absorption 249, 254
extraintestinal manifestations 249
inmunosuppression 248
infection 248
infusion reactions 248
long-acting effects 248, 249
pregnancy 247, 248
regulatory approval 253
safety 246
therapeutic subgroup identification 244, 245, 250
ulcerative colitis treatment 245
Insulin-like growth factor-I
levels 219
Glutamine supplementation effects on
suppression by interleukin-6 173
Insulin-like growth factor binding proteins, intestinal lumen signaling to mucosal immune system 130, 131
Interleukin-1, inflammatory bowel disease
role 49, 52–55, 60
Interleukin-1
acute phase response, cytokine cascade 1, 2
anorexia induction 2, 153
dietary fatty acid effects 72, 73
host defense 63, 64
inflammatory bowel disease role 44, 45, 48, 58, 59, 238
metabolic effects during infection and injury 65, 66
Interleukin-2, inflammatory bowel disease
role 49
Interleukin-4, inflammatory bowel disease
role 46, 48, 49, 58, 238
Interleukin-5, inflammatory bowel disease role 58
Interleukin-6, acute phase response, cytokine cascade 1, 2
dietary fatty acid effects 72, 73
host defense 63, 64
inflammatory bowel disease role 45, 55
suppression of insulin-like growth factor-I levels 173
Interleukin-7, inflammatory bowel disease role 55
Interleukin-8, inflammatory bowel disease role 55
intestinal lumen signaling to mucosal immune system 129
Interleukin-10, inflammatory bowel disease role 46, 61, 238
Interleukin-12, inflammatory bowel disease role 49, 238
Interleukin-13, inflammatory bowel disease role 46, 48
Intestinal epithelial cell 50
apoptosis 51, 53, 54, 59, 60
cytokine production and inflammatory bowel disease role 55, 56
differentiation 51
gene expression regulation by nutrients
breast milk and gene expression in enterocytes 125, 126
butyrate 135–137
enterocyte adaptation 123–125
overview 122, 123
polarity of nutrient-gene interactions in epithelia 123
immune mediated alterations of turnover 50–54
lumen signaling to mucosal immune system
chemokine secretion 128, 129
class II major histocompatibility complex and invariant chain expression 129, 130, 132
insulin-like growth factor binding proteins 130, 131
overview 127, 128
therapeutic implications 131, 132
Intestinal flora, inflammatory bowel disease role 50, 186
Iron deficiency, management with inflammatory bowel disease 162–164, 167–169
Irritable bowel syndrome, diagnosis 94
Lactoferrin, breast milk ingestion effects on intestinal cell gene expression 125, 126
Linkage studies
ethnic groups 34, 38, 39
genome-wide scanning overview 30, 31, 38
HLA-DRB1 locus 34
limitations 31, 32
susceptibility loci in inflammatory bowel disease 32–35
Macrophage inflammatory protein-2, intestinal lumen signaling to mucosal immune system 129, 135
Major histocompatibility complex, class II molecule invariant chain expression, dietary effects 129, 130, 132
Malnutrition, see Protein-energy malnutrition
6-Mercaptopurine, inflammatory bowel disease treatment 139, 237
Mesalamine, inflammatory bowel disease treatment 139
Metronidazole, inflammatory bowel disease treatment 139
Microscopic colitis
course in children 119
features 81
Monocyte chemoattractant protein-1, inflammatory bowel disease role 48, 49
Mycobacterium paratuberculosis, infection and inflammatory bowel disease risk 16, 44
NFκB
human immunodeficiency virus replication response 64
oxidative activation and stimulation of cytokine production 67, 78
Nonsteroidal anti-inflammatory drugs, colitis differential diagnosis from inflammatory bowel disease 96
Nutrition, see Diet
Oral contraceptives, inflammatory bowel disease risk factor 13
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporosis, management with inflammatory bowel disease 161, 162</td>
</tr>
<tr>
<td>Pectin, supplementation of liquid diets 186</td>
</tr>
<tr>
<td>Perforation, risk with ulcerative colitis 86</td>
</tr>
<tr>
<td>Perinuclear antineutrophil cytoplasmic autoantibody, expression in inflammatory bowel disease(s) 99, 117, 118, 120</td>
</tr>
<tr>
<td>Physical inactivity, inflammatory bowel disease risk factor 14</td>
</tr>
<tr>
<td>Positron emission tomography, inflammatory bowel disease diagnosis in children 118</td>
</tr>
</tbody>
</table>
| Pouchitis  
  activity index 90  
  features 91 |
| Probiotics, inflammatory bowel disease treatment 186 |
| Protein-energy malnutrition  
  causes in inflammatory bowel disease 140, 155, 156, 218  
  Crohn’s disease 3, 4, 156  
  cytokine induction in systemic inflammatory response 2, 3  
  ulcerative colitis 3, 4 |
| Quality of life, scoring in inflammatory bowel disease treatment 150 |
| Radiology, inflammatory lesions in gastrointestinal tract 95 |
| RANTES, inflammatory bowel disease role 48, 49 |
| Risk factors, inflammatory bowel disease  
  diet 13, 14, 18–21  
  early life exposures 15, 16  
  familial history 23–25, 37, 42  
  infection 16, 19, 20, 43, 44  
  oral contraceptives 13  
  physical inactivity 14  
  socioeconomic status 14  
  stress 14, 15  
  tobacco use 11–13, 16 |
| Salazopyrine, inflammatory bowel disease treatment 139 |
| Smoking, see Tobacco |
| Socioeconomic status, inflammatory bowel disease risk factor 14 |
| Stress, inflammatory bowel disease risk factor 14, 15 |
| Sucrase, nutrient control of expression in enterocyte 124, 125 |
| Systemic inflammatory response, diagnostic criteria 1 |
| T cell  
  CD4+ cell activation in inflammatory bowel disease 56  
  CD4+ cell suppression with monoclonal antibodies 241  
  helper cell cytokines, roles in inflammatory bowel disease 49, 58 |
| Tobacco, inflammatory bowel disease risk factor 11–13, 16 |
| Total parenteral nutrition, inflammatory bowel disease treatment  
  Crohn’s disease 140, 141, 157  
  efficacy compared to other treatments 142, 146, 156, 157, 168  
  electrolyte replacement 170  
  gastrointestinal fistula management 159, 167  
  glutamine supplementation 157, 158, 232, 233  
  home administration in Crohn’s disease complications 159, 160, 169  
  outcomes 159, 160  
  preoperative therapy 151, 158  
  recommendations for use 165  
  ulcerative colitis 141, 142 |
| Toxic megacolon, risk with ulcerative colitis 86 |
| Transforming growth factor-ß  
  CT3211 nutritional therapy, composition and response in children 191, 192, 194, 196–198  
  inflammatory bowel disease role 48, 238 |
| Treatment, inflammatory bowel disease  
  5-aminosalicylic acid 101, 147, 208, 237  
  azathioprine 139, 152, 237  
  budesonide 139, 152  
  butyrate, inflammation control 145  
  complications and management  
  anemia  
  cobalamin deficiency 164, 165  
  erythropoietin therapy 169  
  iron deficiency 162–164, 167–169  
  osteoporosis 161, 162  
  overview 88, 89 |
corticosteroids 139, 175, 176, 178, 179, 184, 237

cyclosporine 253

elimination diets, Crohn’s disease treatment 145, 147

enteral nutrition
adjunctive support vs primary treatment 174
disease remission compared to drug therapy 142–144, 146, 147
gut-trophic growth factors 217

intestinal atrophy reversal after total parental nutrition 157, 158

meta-analysis of studies 144, 174–177

pediatric treatment, see also CT3211
acceptance and compliance 180, 181, 187
corticosteroid efficacy comparison 175, 176, 178, 179, 183
cyclical nutrition 180
drug treatment factors 149
erly recurrence of active disease 180

elemental vs non-elemental diets 179
formula composition and efficacy 178

mechanism of action 177, 178, 187, 188

meta-analysis of efficacy 174–177

site-specific efficacy 179, 180

supplemental nutrition 180

preoperative therapy 150

relapse 149

fish oil supplementation
clinical studies, history 201–203
rationale 200
relapse prevention 4, 43
study of 45% EPA/20% DHA derivative
absorption and tolerance 204, 205
composition of supplement 203, 204, 211–215
Crohn’s disease treatment 205–208
duration of treatment 212
gut resection patient treatment 208

study design 204

ulcerative colitis treatment 209

flavor packets and diet compliance 153

glutamine supplementation
alternative compounds for administration 224, 232
antioxidant capacity effects 221–223
cell swelling hypothesis in mechanism 231
clinical trials and beneficial effects 224–227, 230
conditional essentiality 218, 219
experimental colitis models 223
experimental short bowel syndrome and jejunal transplantation 220
gut barrier function effects 221
gut trophic growth factor coadministration 233

immunotherapy
CD4+ T cell suppression 241
goals 240
6-mercaptopurine 139, 237
mesalamine 139
metronidazole 139

overview 101

placebo effect 139

probiotics 186

quality of life scoring 150

relapse rates 152

salazopyrine 139

total parenteral nutrition and bowel rest Crohn’s disease 140, 141, 157
efficacy compared to other treatments 142, 146, 156, 157, 168
electrolyte replacement 170
gastrointestinal fistula management 159, 167
home administration in Crohn’s disease complications 159, 160, 169
outcomes 159, 160
Subject Index

Treatment, inflammatory bowel disease
  total parenteral nutrition and bowel rest
  (continued)
    preoperative therapy 151, 158
    recommendations for use 165
    ulcerative colitis 141, 142
  tumor necrosis factor-α monoclonal
  antibody therapy
    CDP571
      anti-antibody response 247
      Crohn’s disease treatment 243
      features 241
      multiple infusions 244
      safety 246
      ulcerative colitis treatment 245
      cost 252
      humanization of antibodies 240
      infliximab
        anti-antibody response 246
        Crohn’s disease treatment 241–243
        features 241
        multiple infusions 243, 244
        safety 246
        ulcerative colitis treatment 245
      nutrition response 254, 255
      precautions
        cancer 249, 255
        children 249, 253, 254
        dosing 250
        drug absorption 249, 254
        extraintestinal manifestations 249
        immunosuppression 248
        infection 248
        infusion reactions 248
        long-acting effects 248, 249
        pregnancy 247, 248
        regulatory approval 253
        therapeutic subgroup identification 244, 245, 250
  Tuberculosis, differential diagnosis from
  inflammatory bowel disease 118
  Tumor necrosis factor-α
    acute phase response, cytokine cascade 1, 2
    amino acid metabolism effects 69, 70
    anorexia induction 2, 153
    biological activities and elevation in
    disease 239
    dietary fatty acid effects 72, 73
    host defense 63, 64, 67
    inflammatory bowel disease role 45, 46, 52–55, 58–60, 238–240
    metabolic effects during infection and
    injury 65, 66
    monoclonal antibody therapy
      CDP571
        anti-antibody response 247
        Crohn’s disease treatment 243
        features 241
        multiple infusions 244
        safety 246
      ulcerative colitis treatment 245
      cost 252
      humanization of antibodies 240
      infliximab
        anti-antibody response 246
        Crohn’s disease treatment 241–243
        features 241
        multiple infusions 243, 244
        safety 246
        ulcerative colitis treatment 245
      nutrition response 254, 255
      precautions
        cancer 249, 255
        children 249, 253, 254
        dosing 250
        drug absorption 249, 254
        extraintestinal manifestations 249
        immunosuppression 248
        infection 248
        infusion reactions 248
        long-acting effects 248, 249
        pregnancy 247, 248
        regulatory approval 253
        therapeutic subgroup identification 244, 245, 250
  Tumor necrosis factor-β, inflammatory
  bowel disease role 49
  Turner syndrome, inflammatory bowel
  disease association 39
  Twin studies, inflammatory bowel disease
  heredity 24, 37

Ulcerative colitis
  complications
    colon cancer 86, 102, 104
    perforation 86
    toxic megacolon 86
    course 86, 87
  diagnosis
    children
      abdominal pain 117
      colonoscopy 114, 115
      histological diagnosis 110
      laborotary tests 113, 114, 117, 118, 120
      overview 113
    clinical trial criteria 99
    differential diagnosis
      infectious colitis 97
      overview 96
differentiation from Crohn’s disease 98, 99, 102, 104, 105
extradigestive symptoms 85, 86, 93, 94
inflammatory lesion demonstration in gastrointestinal tract 95
rectocolonic symptoms 84, 85, 93, 94
discovery 7
enteral nutrition in children 185
incidence studies, see Incidence studies, inflammatory bowel disease
pathology 83, 84
protein-energy malnutrition, overview 3, 4
rating scales of severity 83–85
risk factors, see Risk factors, inflammatory bowel disease
treatment, see Treatment, inflammatory bowel disease
Ultrasound, inflammatory lesions in gastrointestinal tract 95
Vitamin A, intake and anti-inflammatory activity 72
Vitamin C, intake and anti-inflammatory activity 71
Vitamin E, intake and anti-inflammatory activity 71, 78
Zinc
deficiency in inflammatory bowel disease 184
metabolic response in inflammation 65, 66